IMN || Rheumatology

New agent builds bone bigger, faster

Posted on: 17/07/2014 - 15:50

CHICAGO – Abaloparatide, a synthetic analog of human parathyroid hormone–related peptide, displayed jaw-dropping superiority to teriparatide in boosting bone mineral density at multiple anatomic...

Field of Interest: Rheumatology
Type: News Item

Telecare intervention lessens chronic joint pain

Posted on: 15/07/2014 - 21:05

A telecare intervention within the primary care practice setting elicited clinically meaningful and statistically significant improvements in long-standing chronic joint and other musculoskeletal...

Field of Interest: Rheumatology
Type: News Item

Fractures increased with two diabetes drugs

Posted on: 15/07/2014 - 18:40

SAN FRANCISCO – Adults who started taking sulfonylurea drugs for diabetes were 9% more likely to develop fractures within 5 years, and patients starting thiazolidinediones were 9% more likely to have...

Field of Interest: Rheumatology
Type: News Item

Rituximab yielded long-term benefit in lupus nephritis

Posted on: 10/07/2014 - 21:30

PARIS – Treatment with rituximab in patients with refractory lupus nephritis was associated with significant long-term improvement in symptoms, histology, and laboratory markers in a prospective...

Field of Interest: Rheumatology
Type: News Item

Trial of sirukumab for lupus nephritis falls flat

Posted on: 08/07/2014 - 21:20

PARIS – The investigational interleukin-6 blocker sirukumab provided no benefit to patients with lupus nephritis but put them at a very high risk of developing a serious infection in a small,...

Field of Interest: Rheumatology
Type: News Item

Real-world use supports belimumab clinical trial data

Posted on: 08/07/2014 - 16:20

PARIS – Belimumab produced significant clinical improvement in 74% of patients with systemic lupus erythematosus who took it over a 6-month period, reducing disease symptoms and steroid use and...

Field of Interest: Rheumatology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More